- Home
- BQ vs ENLV Comparison
BQ vs ENLV Comparison
Compare BQ & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- ENLV
- Stock Information
- Founded
- BQ 2008
- ENLV 2005
- Country
- BQ China
- ENLV Israel
- Employees
- BQ N/A
- ENLV N/A
- Industry
- BQ Other Specialty Stores
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- ENLV Health Care
- Exchange
- BQ Nasdaq
- ENLV Nasdaq
- Market Cap
- BQ 25.0M
- ENLV 25.8M
- IPO Year
- BQ 2020
- ENLV 1995
- Fundamental
- Price
- BQ $7.73
- ENLV $1.07
- Analyst Decision
- BQ
- ENLV Strong Buy
- Analyst Count
- BQ 0
- ENLV 2
- Target Price
- BQ N/A
- ENLV $10.00
- AVG Volume (30 Days)
- BQ 3.5M
- ENLV 172.3K
- Earning Date
- BQ 07-21-2025
- ENLV 11-28-2025
- Dividend Yield
- BQ N/A
- ENLV N/A
- EPS Growth
- BQ N/A
- ENLV N/A
- EPS
- BQ N/A
- ENLV N/A
- Revenue
- BQ $64,617,102.00
- ENLV N/A
- Revenue This Year
- BQ N/A
- ENLV N/A
- Revenue Next Year
- BQ N/A
- ENLV N/A
- P/E Ratio
- BQ N/A
- ENLV N/A
- Revenue Growth
- BQ N/A
- ENLV N/A
- 52 Week Low
- BQ $1.62
- ENLV $0.81
- 52 Week High
- BQ $46.70
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- BQ 48.24
- ENLV 45.62
- Support Level
- BQ $7.71
- ENLV $1.03
- Resistance Level
- BQ $8.62
- ENLV $1.16
- Average True Range (ATR)
- BQ 4.42
- ENLV 0.05
- MACD
- BQ -0.66
- ENLV -0.00
- Stochastic Oscillator
- BQ 0.77
- ENLV 16.67
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.